While MV4:11 and MOLM13 cells were chosen for our experiments because both cell lines are derived from KMT2Ar AML, the potential of our treatment approach for FLT3-ITD-positive AML results from the high frequency of co-occurring NPM1c in these patients [27,28]. Here, FLT3 is linked to acute myeloid leukemia.